Wenzhou Kangning Hospital Co., Ltd. (HKG:2120)
Hong Kong · Delayed Price · Currency is HKD 8.50
-0.11 (-1.28%)
At close: Mar 27, 2026
Wenzhou Kangning Hospital Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,449 | 1,518 | 1,485 | 1,367 | 1,203 |
Other Revenue | 171.08 | 136.52 | 111.1 | 118.09 | 94.66 |
| 1,620 | 1,654 | 1,596 | 1,485 | 1,297 | |
Revenue Growth (YoY) | -2.09% | 3.64% | 7.50% | 14.45% | 31.18% |
Cost of Revenue | 1,201 | 1,227 | 1,197 | 1,140 | 976.16 |
Gross Profit | 419.07 | 427.48 | 399.3 | 344.88 | 321.27 |
Selling, General & Admin | 240.84 | 226.4 | 218.29 | 212.84 | 178.98 |
Research & Development | 30.12 | 36.52 | 32.47 | 33.03 | 27.96 |
Other Operating Expenses | -12.31 | -0.92 | -9.5 | 4.65 | 5.62 |
Operating Expenses | 273.14 | 281.11 | 248.43 | 261.79 | 215.57 |
Operating Income | 145.93 | 146.37 | 150.87 | 83.1 | 105.7 |
Interest Expense | -45.75 | -49.5 | -45.63 | -45.15 | -36.27 |
Interest & Investment Income | 4.2 | 3.88 | 5.27 | 5.61 | 8.63 |
Currency Exchange Gain (Loss) | -0.03 | -0.16 | 0 | 0.08 | -0.04 |
Other Non Operating Income (Expenses) | -7.66 | -8.4 | -1.07 | -15.93 | -2.18 |
EBT Excluding Unusual Items | 96.69 | 92.19 | 109.44 | 27.71 | 75.85 |
Impairment of Goodwill | -11.5 | -5.75 | - | -10.35 | -6.18 |
Gain (Loss) on Sale of Investments | -3.02 | -11.02 | -5.85 | -15.98 | 9.42 |
Gain (Loss) on Sale of Assets | -11.62 | -0.07 | 0.07 | 0.41 | -0.08 |
Asset Writedown | -1.33 | -0.96 | -0.26 | -1.57 | -0.01 |
Other Unusual Items | - | -6.29 | -4.21 | 15.39 | 16.7 |
Pretax Income | 69.22 | 68.1 | 99.18 | 15.6 | 95.69 |
Income Tax Expense | 32.62 | 17.7 | 12.25 | 26.57 | 54.83 |
Earnings From Continuing Operations | 36.6 | 50.4 | 86.93 | -10.97 | 40.86 |
Minority Interest in Earnings | 17.79 | 15.21 | -0.98 | -13.25 | 3.18 |
Net Income | 54.4 | 65.61 | 85.95 | -24.22 | 44.04 |
Net Income to Common | 54.4 | 65.61 | 85.95 | -24.22 | 44.04 |
Net Income Growth | -17.09% | -23.66% | - | - | -21.04% |
Shares Outstanding (Basic) | 72 | 74 | 75 | 75 | 72 |
Shares Outstanding (Diluted) | 72 | 74 | 75 | 75 | 75 |
Shares Change (YoY) | -3.13% | -0.43% | - | - | 0.91% |
EPS (Basic) | 0.76 | 0.88 | 1.15 | -0.32 | 0.61 |
EPS (Diluted) | 0.76 | 0.88 | 1.15 | -0.32 | 0.59 |
EPS Growth | -14.09% | -23.48% | - | - | -21.33% |
Free Cash Flow | 250.46 | -92.54 | 85.3 | -9.69 | 15.36 |
Free Cash Flow Per Share | 3.48 | -1.25 | 1.14 | -0.13 | 0.21 |
Dividend Per Share | 0.500 | 0.450 | 0.400 | - | - |
Dividend Growth | 11.11% | 12.50% | - | - | - |
Gross Margin | 25.87% | 25.84% | 25.01% | 23.23% | 24.76% |
Operating Margin | 9.01% | 8.85% | 9.45% | 5.60% | 8.15% |
Profit Margin | 3.36% | 3.97% | 5.38% | -1.63% | 3.39% |
Free Cash Flow Margin | 15.46% | -5.59% | 5.34% | -0.65% | 1.18% |
EBITDA | 282.79 | 234.08 | 223.82 | 159.12 | 168.51 |
EBITDA Margin | 17.46% | 14.15% | 14.02% | 10.72% | 12.99% |
D&A For EBITDA | 136.86 | 87.71 | 72.95 | 76.02 | 62.81 |
EBIT | 145.93 | 146.37 | 150.87 | 83.1 | 105.7 |
EBIT Margin | 9.01% | 8.85% | 9.45% | 5.60% | 8.15% |
Effective Tax Rate | 47.12% | 25.99% | 12.35% | 170.29% | 57.30% |
Revenue as Reported | 1,620 | 1,654 | 1,596 | 1,485 | 1,297 |
Advertising Expenses | - | 3.7 | 4.5 | 3.53 | 2.99 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.